Imurel

Azathioprine, the active ingredient in Imurel, is an immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease in adult patients.

GNH USA supplies Imurel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and timely delivery across multiple regions.

Azathioprine is used in immunologic and inflammatory disease pathways to modulate immune activity. - Organ transplant rejection: helps prevent graft rejection by suppressing lymphocyte proliferation. - Rheumatoid arthritis: reduces joint inflammation and disease progression in patients with active disease. - Inflammatory bowel disease: induces and maintains remission in Crohn’s disease and ulcerative colitis.

Azathioprine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset often occurring after dosing. - Vomiting: occasional episodes of stomach upset. - Diarrhea: loose stools that may be transient. - Fatigue: general tiredness or lack of energy. - Elevated liver enzymes: mild, reversible changes in hepatic function tests. - Decreased white blood cell count: mild leukopenia detectable on routine labs.

Serious or Rare Side Effects: - Severe bone marrow suppression: pancytopenia requiring medical intervention. - Hepatotoxicity: significant liver injury with jaundice or elevated transaminases. - Increased risk of infections: opportunistic infections due to immunosuppression. - Malignancies: higher incidence of lymphomas and skin cancers with long‑term use. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Before initiating azathioprine therapy, several precautions should be observed to ensure patient safety. - Baseline monitoring: obtain complete blood count and liver function tests prior to treatment. - Ongoing monitoring: regularly assess blood counts and hepatic enzymes during therapy. - Infection risk: avoid live vaccines and monitor for signs of infection. - Renal impairment: adjust dose or increase monitoring in patients with reduced kidney function. - Pregnancy and lactation: evaluate risks and benefits; use only if clearly indicated. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Azathioprine interacts with several medicines; awareness of these interactions helps prevent toxicity or loss of efficacy.

Major Interactions (Avoid): - Allopurinol or febuxostat: markedly increase azathioprine toxicity; concurrent use is contraindicated. - Warfarin: azathioprine may enhance anticoagulant effect, raising INR and bleeding risk. - Live vaccines: combined immunosuppression can lead to severe infection.

Moderate Interactions (Monitor Closely): - NSAIDs: may further impair renal function and increase gastrointestinal irritation. - Sulfonamide antibiotics: can add to bone marrow suppression. - ACE inhibitors or ARBs: may potentiate renal effects, requiring closer monitoring of kidney function.